{"disease":{"id":"portal-vein-tumor-thrombus","name":"portal vein tumor thrombus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03322280","title":"TACE Combined With Iodine-125 Seeds Implantation for HCC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":270,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05984511","title":"TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT","phase":"NA","overall_status":"RECRUITING","enrollment_count":234,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04319484","title":"Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":108,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04619342","title":"Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":98,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT04127396","title":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT03178656","title":"A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07062055","title":"BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT06622031","title":"TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT","phase":"NA","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04069949","title":"Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":39,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT04850157","title":"Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04618367","title":"HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06040177","title":"Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"First Affiliated Hospital of Guangxi Medical University","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}